Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of rADAMTS-13 (apadamtase alfa) in acquired thrombotic thrombocytopenic purpura
2018-003775-35Phase 2Unknown
- Sponsor
- Baxalta
- Start
- Feb 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in thrombotic thrombocytopenic purpura (TTP) comparing Apadamtase alfa + standard of care with Placebo + standard of care (2 arms). Primary endpoint: ADAMTS-13 activity levels. Status: unknown.
02
Drugs
Apadamtase alfa
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2018-003775-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003775-35.